| Project/Area Number |
18K09243
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56040:Obstetrics and gynecology-related
|
|---|
| Research Institution | Miyagi Prefectural Hospital Organization Miyagi Cancer Center |
|---|
Principal Investigator |
Yamada Hidekazu 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん薬物療法研究部, 特任研究員 (10254012)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
田沼 延公 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん薬物療法研究部, 主任研究員 (40333645)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 卵巣がん / 標的治療 / 代謝 / BRCA / DNA修復 |
|---|
| Outline of Final Research Achievements |
The aim of this study is identifying metabolic vulnerability of ovarian cancer for the development of new molecular-targeting therapy in that cancer. To do so, we performed CRISPR/Cas9 screening using two ovarian cancer cell lines, namely CAOV3 and es2 cells. We identified 42 and 119 essential metabolic genes in CAOV3 and es2 cells, respectively. Importantly, 33 genes of them are overlapped. Mapping of the overlapping genes in metabolic network may represent pathway(s) whose inhibition result in cell-death of ovarian cancer.
|
| Academic Significance and Societal Importance of the Research Achievements |
創薬標的化が可能なドライバー遺伝子変異が少ない卵巣がんにおいて、新規治療シーズの開拓は非常に重要である。本研究において取得した代謝（関連）遺伝子のリストは、卵巣がんの代謝脆弱ポイントを網羅すると予想され、今後、新たな標的治療への展開を期待できる。
|
